Skip to main content

Advertisement

SpringerLink
Log in

Prevention and treatment of high-altitude illness in travelers

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

High-altitude illness is the collective term for acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE). These syndromes can affect unacclimatized travelers shortly after ascent to high altitude (especially higher than 2500 m). AMS is relatively common and usually is mild and self-limiting; HACE and HAPE are uncommon but life-threatening. Gradual ascent is the best strategy for preventing or minimizing high-altitude illness, although chemoprophylaxis may be useful in some situations. Acetazolamide remains the chemoprophylactic agent of choice, although other drugs, such as gingko biloba, are being investigated. Immediate descent remains the cornerstone of treatment for HACE and HAPE, although pharmacologic and hyperbaric therapies may facilitate this process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. World Health Organization: World health statistics annual 1995. Geneva: World Health Organization; 1996.

    Google Scholar 

  2. Honigman B, Theis MK, Koziol-McLain J, et al.: Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med 1993, 118:587–592.

    PubMed  CAS  Google Scholar 

  3. Hackett PH, Rennie D, Levine HD: The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976, 2:1149–1155. This is a landmark paper describing the epidemiology of AMS among travelers in the Mt. Everest region of Nepal.

    Article  PubMed  CAS  Google Scholar 

  4. Hackett PH, Rennie D: Rales, peripheral edema, retinal hemorrhage and acute mountain sickness. Am J Med 1979, 67:214–218.

    Article  PubMed  CAS  Google Scholar 

  5. Murdoch DR: Altitude illness among tourists flying to 3740 meters elevation in the Nepal Himalayas. J Travel Med 1995, 2:255–256.

    Article  PubMed  Google Scholar 

  6. Maggiorini M, Bühler B, Walter M, Oelz O: Prevalence of acute mountain sickness in the Swiss Alps. BMJ 1990, 301:853–855.

    PubMed  CAS  Google Scholar 

  7. Gabry AL, Ledoux X, Mozziconacci M, Martin C: High-altitude pulmonary edema at moderate altitude (<2,400 m; 7870 feet). A series of 52 patients. Chest 2003, 123:49–53.

    Article  PubMed  Google Scholar 

  8. Roach RC, Maes D, Sandoval D, et al.: Exercise exacerbates acute mountain sickness at simulated high altitude. J Appl Physiol 2000, 88:581–585.

    PubMed  CAS  Google Scholar 

  9. Milledge JS, Beeley JM, Broome J, et al.: Acute mountain sickness susceptibility, fitness and hypoxic ventilatory response. Eur Respir J 1991, 4:1000–1003.

    PubMed  CAS  Google Scholar 

  10. Bircher HP, Eichenberger U, Maggiorini M, et al.: Relationship of mountain sickness to physical fitness and exercise intensity during ascent. J Wilderness Med 1994, 5:302–311.

    Google Scholar 

  11. Pollard AJ, Niermeyer S, Barry P, et al.: Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol 2001, 2:389–403. This review and consensus statement summarizes current knowledge regarding the health problems of children at high altitude.

    Article  PubMed  CAS  Google Scholar 

  12. Roach RC, Houston CS, Hongiman B, et al.: How well do older persons tolerate moderate altitude? West J Med 1995, 162:32–36.

    PubMed  CAS  Google Scholar 

  13. Kayser B: Acute mountain sickness in western tourists around the Thorong pass (5400 m) in Nepal. J Wilderness Med 1991, 2:110–117.

    Google Scholar 

  14. Murdoch DR, Curry C: Acute mountain sickness in the Southern Alps of New Zealand. N Z Med J 1998, 111:168–169.

    PubMed  CAS  Google Scholar 

  15. Basnyat B: Neck irradiation or surgery may predispose to severe acute mountain sickness. J Travel Med 2002, 9:105.

    Article  PubMed  Google Scholar 

  16. Murdoch DR: Symptoms of infection and altitude illness among hikers in the Mount Everest region of Nepal. Aviat Space Environ Med 1995, 66:148–151.

    PubMed  CAS  Google Scholar 

  17. Durmowicz AG, Noordeweir E, Nicholas R, Reeves JT: Inflammatory processes may predispose children to high-altitude pulmonary edema. J Pediatrics 1997, 130:838–840.

    CAS  Google Scholar 

  18. Silber E, Sonnenberg P, Collier DJ, et al.: Clinical features of headache at altitude: a prospective study. Neurology 2003, 60:1167–1171.

    PubMed  CAS  Google Scholar 

  19. Hackett PH, Creagh CE, Grover RF, et al.: High-altitude pulmonary edema in persons without the right pulmonary artery. N Engl J Med 1980, 302:1070–1073.

    Article  PubMed  CAS  Google Scholar 

  20. Naeije R, De Backer D, Vachiery JL, De Vuyst P: High-altitude pulmonary edema with primary pulmonary hypertension. Chest 1996, 110:286–289.

    PubMed  CAS  Google Scholar 

  21. Vock P, Brutsche MH, Nanzer A, Bärtsch P: Variable radiomorphologic data of high altitude pulmonary edema. Features from 60 patients. Chest 1991, 100:1306–1311.

    PubMed  CAS  Google Scholar 

  22. Basnyat B, Murdoch DR: High-altitude illness. Lancet 2003, 361:1967–1974. This is a recent review of high-altitude illness, with an emphasis on recent developments in pathogenesis, prevention, and treatment.

    Article  PubMed  Google Scholar 

  23. Hackett PH: The cerebral etiology of high-altitude cerebral edema and acute mountain sickness. Wilderness Environ Med 1999, 10:97–109.

    PubMed  CAS  Google Scholar 

  24. Roach RC, Hackett PH: Frontiers of hypoxia research: acute mountain sickness. J Exp Biol 2001, 204:3161–3170. This is a detailed review of AMS pathogenesis and related research.

    PubMed  CAS  Google Scholar 

  25. Swenson ER, Maggiorini M, Mongovin S, et al.: Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. JAMA 2002, 287:2228–2235.

    Article  PubMed  Google Scholar 

  26. Sartori C, Allemann Y, Duplain H, et al.: Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002, 346:1631–1636.

    Article  PubMed  CAS  Google Scholar 

  27. Murdoch DR: How fast is too fast? Attempts to define a recommended ascent rate to prevent acute mountain sickness. News Int Soc Mt Med 1999, 9:3–6.

    Google Scholar 

  28. Hackett PH, Roach RC: High-altitude illness. N Engl J Med 2001, 345:107–114. This is a general review of high-altitude illness.

    Article  PubMed  CAS  Google Scholar 

  29. Vann R, Pollock N, Pieper C, et al.: Epidemiological models of acute mountain sickness (AMS). High Alt Med Biol 2003, 4:451.

    Google Scholar 

  30. Basnyat B, Gertsch JH, Johnson W, et al.: Efficacy of low dose acetazolamide (125 mg bid) in the prophylaxis of acute mountain sickness. High Alt Med Biol 2003, 4:45–52.

    Article  PubMed  CAS  Google Scholar 

  31. Dumont L, Mardirosoff C, Tramèr MR: Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 2000, 321:267–272.

    Article  PubMed  CAS  Google Scholar 

  32. Hackett PH, Roach RC, Wood RA, et al.: Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med 1988, 59:950–954.

    PubMed  CAS  Google Scholar 

  33. Johnson TS, Rock PB, Fulco CS, et al.: Prevention of acute mountain sickness by dexamethasone. N Engl J Med 1984, 310:683–686.

    Article  PubMed  CAS  Google Scholar 

  34. Ellsworth AJ, Meyer EF, Larson EB: Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med 1991, 154:289–293.

    PubMed  CAS  Google Scholar 

  35. Ried LD, Carter KA, Ellsworth A: Acetazolamide or dexamethasone for prevention of acute mountain sickness: a metaanalysis. J Wilderness Med 1994, 5:34–48.

    Google Scholar 

  36. Bernhard WN, Schalick LM, Delaney PA, et al.: Acetazolamide plus low-dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviat Space Environ Med 1998, 69:883–886.

    PubMed  CAS  Google Scholar 

  37. Roncin JP, Schwartz F, D’Arbigny P: EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med 1996, 67:445–452.

    PubMed  CAS  Google Scholar 

  38. Leadbetter G, Maakestad K, Olson S, Hackett P: Gingko biloba reduces incidence and severity of acute mountain sickness. High Alt Med Biol 2001, 2:110.

    Google Scholar 

  39. Gertsch JH, Seto TB, Mor J, Onopa J: Gingko biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol 2002, 3:29–37.

    Article  PubMed  Google Scholar 

  40. Bailey DM, Davies B: Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude. High Alt Med Biol 2001, 2:21–29.

    Article  PubMed  CAS  Google Scholar 

  41. Bärtsch P, Maggiorini M, Ritter M, et al.: Prevention of highaltitude pulmonary edema by nifedipine. N Engl J Med 1991, 325:1284–1289.

    Article  PubMed  Google Scholar 

  42. Grissom CK, Roach RC, Sarnquist FH, Hackett PH: Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 1992, 116:461–465.

    PubMed  CAS  Google Scholar 

  43. Levine BD, Yoshimura K, Kobayashi T, et al.: Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989, 321:1707–1713.

    Article  PubMed  CAS  Google Scholar 

  44. Ferrazzini G, Maggiorini M, Kriemler S, et al.: Successful treatment of acute mountain sickness with dexamethasone. BMJ 1987, 294:1380–1382.

    Article  PubMed  CAS  Google Scholar 

  45. Davis PR, Kippax J, Shaw GM, et al.: A novel continuous positive airways pressure (CPAP) device for use at high altitude. High Alt Med Biol 2002, 3:101.

    Google Scholar 

  46. Oelz O, Maggiorini M, Ritter M, et al.: Nifedipine for high altitude pulmonary oedema. Lancet 1989, 2:1241–1244.

    Article  PubMed  CAS  Google Scholar 

  47. Kasic JF, Yaron M, Nicholas RA, et al.: Treatment of acute mountain sickness: hyperbaric versus oxygen therapy. Ann Emerg Med 1991, 20:1109–1112.

    Article  PubMed  CAS  Google Scholar 

  48. Bärtsch P, Merki B, Hofstetter D, et al.: Treatment of acute mountain sickness by simulated descent: a randomised controlled trial. BMJ 1993, 306:1098–1101.

    PubMed  Google Scholar 

  49. Keller HR, Maggiorini M, Bärtsch P, Oelz O: Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial. BMJ 1995, 310:1232–1235.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand

    David R. Murdoch MD, DTM&H, FRACP, FRCPA, FACTM

Authors
  1. David R. Murdoch MD, DTM&H, FRACP, FRCPA, FACTM
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murdoch, D.R. Prevention and treatment of high-altitude illness in travelers. Curr Infect Dis Rep 6, 43–49 (2004). https://doi.org/10.1007/s11908-004-0023-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-004-0023-4

Keywords

Search

Navigation